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1. Introduction 
Functional deterioration of the peritoneum as a dialyzing organ is a leading cause of 
peritoneal dialysis (PD) failure. The problem usually develops 2-4 years after the initiation 
of therapy (Davies et al., 1996; Struijk et al., 1994) and may affect as many as 50% of all PD 
patients (Kawaguchi et al., 1997). The alterations that develop in the peritoneal membrane 
over time include submesothelial thickening, fibrosis, angiogenesis, and vascular 
degeneration (Honda et al., 2008; Mateijsen et al., 1999; Williams et al., 2002; Williams et al., 
2003). These changes are associated with an increase in peritoneal solute transport with 
resultant dissipation of the osmotic gradient and loss of ultrafiltration. Indeed, it has been 
estimated that up to 75% of patients with ultrafiltration failure will have increased vascular 
area (Heimburger et al., 1990; Ho-Dac-Pannekeet et al., 1997). Pathological angiogenesis not 
only increases vascular surface area of the peritoneum but is also a key step in the 
progression of fibrosis (Wynn, 2007). Therefore, it is essential to understand how PD 
environment impacts on peritoneal vasculature.  
2. Vascular endothelial growth factor 
The process of angiogenesis requires tight coordination of cell proliferation, differentiation, 
migration, and cell-matrix interactions. The most important molecules that control blood 
vessel growth and permeability are vascular endothelial growth factors (VEGFs). VEGF-A 
(also designated and further referred to as VEGF) is the founding member of the VEGF 
family and was originally discovered by its ability to enhance vascular permeability (Nagy 
et al., 2007). In mammals, other VEGF family members include VEGF-B, -C, and -D, as well 
as placenta growth factor (PlGF). Structurally, the VEGFs are related to the family of 
platelet-derived growth factors (PDGF) (Olsson et al., 2006). VEGF is a highly conserved, 
disulfide-bonded dimeric glycoprotein, encoded by a single gene. The human Vegf gene is 
located on the short arm of chromosome 6 and alternative RNA splicing gives rise to 
peptide isoforms of 121, 145, 165, 189, and 206 amino acids. VEGF exerts its biologic effects 
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mainly through cell-surface tyrosine kinase receptors VEGFR-2, and - to lesser extent - 
VEGFR-1 (Nagy et al., 2007). Although VEGF isoforms display similar basic activities, their 
bio-availability may be modulated by proteolytic processing and differences in binding to 
co-receptors such as heparan sulphate proteoglycans and neuropilins (Olsson et al., 2006).  
VEGF is an extremely potent and rapid inducer of vascular permeability (Olsson et al., 
2006). This effect depends on the production of nitric oxide (NO) by endothelial NO 
synthase (eNOS). Consequently, targeted deletion of eNOS abrogates VEGF-induced 
permeability (Fukumura et al., 2001). Other biological effects of VEGF include vasodilation, 
endothelial cell proliferation, migration and tube formation. It also delays senescence of 
endothelial cells, promotes their survival, and mobilizes endothelial cell precursors (Nagy et 
al., 2007; Otrock et al., 2007). Inactivation of a single Vegf allele in mice results in early 
embryonic lethality caused by impaired development of endothelial cells and blood vessels 
(Carmeliet et al., 1996; Ferrara et al., 1996). In turn, an increase in VEGF expression is 
commonly associated with pathological angiogenesis observed in malignancies, 
inflammation, and wound healing (Nagy et al., 2007).  
2.1 VEGF in the peritoneal cavity 
Given its role in controlling vascular permeability and proliferation, VEGF became an 
obvious target in research efforts to define the mechanism of peritoneal membrane failure. 
VEGF was promptly detected in the effluent dialysate (Zweers et al., 1999) in concentrations 
higher than could be expected on the basis of simple diffusion from the circulation (Selgas et 
al., 2001; Zweers et al., 1999). This pointed to the local production of VEGF in the 
peritoneum. Moreover, the rate of VEGF appearance in the dialysate was found to increase 
with time on PD (Cho et al., 2010) and to be elevated in patients with high peritoneal 
transport status (Pecoits-Filho et al., 2002; Rodrigues et al., 2007). Further analyses showed 
that the dialysate appearance of VEGF correlated also with that of cancer antigen 125 
(CA125) (Cho et al., 2010; Rodrigues et al., 2004; Rodrigues et al., 2007). CA125 is thought to 
reflect the mass of peritoneal mesothelial cells (Krediet, 2001), therefore the mesothelium 
was considered to be the main source of intraperitoneal VEGF. Indeed, immunochemical 
staining of peritoneal biopsies showed that VEGF expression was confined mainly to the 
mesothelial monolayer (Aroeira et al., 2005; Combet et al., 2000). The mesothelial origin of 
peritoneal VEGF was ultimately confirmed in an elegant study, during which various cell 
types were isolated from the peritoneal lavage and the omentum, and analysed by several 
techniques for the ability to generate VEGF (Gerber et al., 2006). It transpired that omental 
mesothelial cells were responsible for the majority of peritoneal VEGF produced. These 
results were corroborated by the demonstration of constitutive VEGF secretion by 
mesothelial cells isolated either from the dialysate effluent (Selgas et al., 2000) or from the 
omentum (Mandl-Weber et al., 2002). Moreover, VEGF released by mesothelial cells was 
shown to exhibit biologic activity (Boulanger et al., 2007). The formation of capillary tubes 
by endothelial cells in vitro was found to increase either in the presence of peritoneal 
mesothelial cells or after the addition of conditioned medium from mesothelial cell cultures. 
These effects could be abolished by anti-VEGF antibodies (Boulanger et al., 2007).  
3. Mesothelial cell VEGF expression during PD 
The above data have given support to a long held belief that although the mesothelium 
forms only a single-cell layer over the peritoneum, it may significantly impact on the dialytic 
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function of the whole peritoneal membrane by producing powerful mediators that act on 
the peritoneal interstitium and vasculature. Immunochemical analysis of peritoneal biopsies 
revealed only weak mesothelial expression of VEGF in control subjects, but extensive VEGF 
staining in patients undergoing PD (Aroeira et al., 2005; Combet et al., 2000). In an 
interesting experimental model mesothelial cells were isolated from dialysate effluent of PD 
patients, propagated ex vivo and analysed for the ability to release VEGF (Aroeira et al., 
2005). It turned out that mesothelial cells isolated from patients with high peritoneal 
permeability secreted more VEGF compared to cells from patients with lower peritoneal 
transport properties.  
Several factors have been implicated in the pathogenesis of increased peritoneal 
permeability in PD. They include the state of uraemia, episodes of peritonitis, and chronic 
exposure to dialysis fluids (Margetts & Churchill, 2002). Increasing evidence indicate that 
such conditions may modulate the release of VEGF by mesothelial cells. It is therefore 
essential to delineate mesothelial cell responses to these challenges. 
3.1 Peritonitis 
An increase in vascular permeability is a hallmark of inflammation. As a result, when acute 
peritonitis occurs during PD, it leads to rapid absorption of instilled glucose and a decrease 
in osmotic gradient-driven ultrafiltration. Modelling of PD-associated peritonitis in mice 
revealed significant increases in vascular density, the relative endothelial area, and the 
diameter of peritoneal vessels (Ni et al., 2003). These alterations were evident several days 
after bacterial infection and were accompanied by a huge increase in the dialysate VEGF 
concentration.  
The inflammatory response is orchestrated by a coordinated release of cytokines with 
interleukin-1ǃ (IL-1ǃ) and tumour necrosis factor-ǂ (TNFǂ) acting as crucial promoters of 
the reaction. The concentrations of IL-1ǃ and TNFǂ in PD effluent increase very early and 
dramatically in the course of peritonitis (Brauner et al., 1996; Moutabarrik et al., 1995; Zemel 
et al., 1994). Transient, adenovirus-mediated over-expression of either IL-1ǃ or TNFǂ in the 
rat peritoneum was found to increase the expression of VEGF in the peritoneal tissue and 
fluid (Margetts et al., 2002). This effect was followed by extensive angiogenesis, increased 
peritoneal permeability, and impaired ultrafiltration. In keeping with these results, it has 
been demonstrated that either IL-1ǃ or TNFǂ were capable of inducing time- and dose-
dependent VEGF production in mesothelial cells in vitro (Mandl-Weber et al., 2002). 
Moreover, in vitro exposure of mesothelial cells to dialysate effluent drained during 
peritonitis resulted in a significantly increased VEGF release compared to when cells were 
maintained in the non-infected dialysate (Witowski & Jörres, personal observations).  
3.2 Exposure to dialysis fluids 
The observation that the ultrafiltration capacity of the peritoneum decreases with time on 
PD (Davies et al., 1996; Heimburger et al., 1999) suggested that long-term exposure to 
bioincompatible PD fluids might have a deleterious impact on the peritoneal membrane. 
Early experiments pointed to low pH, high concentrations of lactate and glucose, and the 
presence of glucose degradation products (GDPs) as the elements curtailing 
biocompatibility of standard PD solutions (Wieslander et al., 1991). In recent years particular 
attention has been paid to GDPs. They are reactive carbonyl derivatives of glucose (such as 
formaldehyde, methylglyoxal or 3-deoxyglucosone), which are formed predominantly 
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during heat sterilization of PD fluids. It has been demonstrated that conventional PD fluids 
with high GDPs content recruited capillaries and induced vasodilation of mesenteric arteries 
in the rat peritoneum (Mortier et al., 2002). Moreover, the peritonea of rats injected 
intraperitoneally for several days with methylglyoxal were found to display increased 
vascularization (Nakayama et al., 2003) and VEGF expression (Inagi et al., 1999). Subsequent 
experiments confirmed that extensive peritoneal expression of VEGF in rats receiving 
methylglyoxal-containing PD fluids was associated with neoangiogenesis and increased 
permeability (Hirahara et al., 2006). Furthermore, it has been demonstrated that direct in 
vitro exposure of mesothelial cells to several GDPs (methylglyoxal, 3,4-dideoxy-glucosone-
3-ene, 2-furaldehyde) resulted in an increased VEGF expression (Inagi et al., 1999; Lai et al., 
2004; Leung et al., 2005).  
The adverse effects of GDPs on the peritoneal membrane can also be mediated through 
advanced glycation-end products (AGEs). GDPs react with amino groups of proteins to 
form AGEs and it has been demonstrated that PD fluids with high GDP levels significantly 
promote the generation of AGEs (Tauer et al., 2001). Animal experiments showed that 
intraperitoneal infusion of GDP-containing solutions led to the accumulation in the 
peritoneal membrane of both methylglyoxal and AGEs (Mortier et al., 2004). The presence of 
AGE deposits was associated with increased expression of VEGF, increased vascular 
density, and lower ultrafiltration. These observations were in line with earlier data showing 
that the intensity of peritoneal AGE accumulation in PD patients correlated with changes in 
peritoneal transport and ultrafiltration (Honda et al., 1999; Nakayama et al., 1997). 
Moreover, mesothelial cells were found to bear a receptor for AGEs (RAGE) and to up-
regulate its expression following exposure to GDP in either in vitro (Lai et al., 2004) or in 
vivo setting (Mortier et al., 2004). In turn, incubation of mesothelial cells with AGEs led to a 
dose-dependent increase in VEGF production (Boulanger et al., 2007; Mandl-Weber et al., 
2002). Interestingly, GDP-induced VEGF release by mesothelial cells could be reduced by 
aminoguanidine, an inhibitor of AGE formation (Lai et al., 2004). Also, a rise in peritoneal 
VEGF expression and vascular density that was induced in wild-type mice by chronic 
exposure to GDP-containing fluids, did not occur in RAGE-deficient animals (Schwenger et 
al., 2006). Correspondingly, the promoting effect of AGE-treated mesothelial cells on 
capillary tube formation could be substantially diminished by the blockade of RAGE with 
specific antibodies (Boulanger et al., 2007). These data indicate that GDPs exert their effect 
by inducing glycation of proteins that subsequently activate RAGE on mesothelial cells and 
stimulate them to release angiogenic VEGF (Fig. 1).  
3.3 Uraemia 
After analysing peritoneal specimens from a large cohort of individuals, the Peritoneal 
Biopsy Study Group concluded that in many patients with uraemia some changes in the 
peritoneum occurred even before the commencement of PD (Williams et al., 2002). 
Compared to healthy individuals, such patients often had significant thickening of the 
submesothelial compact zone and extensive vasculopathy. These changes are generally 
attributed to the build-up of uraemic toxins, however, their exact nature remains poorly 
defined. The peritonea of rats made uraemic by subtotal nephrectomy were found to have 
increased permeability and showed focal areas of vascular proliferation, up-regulation of 
VEGF and accumulation of AGEs (Combet et al., 2001). Furthermore, there was the evidence 
of mesothelial cell conversion into myofibroblasts (De Vriese et al., 2006). A more recent 
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study in humans confirmed the presence of submesothelial thickening, focal fibrosis, and 
increased vascularization in the uraemic peritoneum (Kihm et al., 2008). These alterations 
were accompanied by increased peritoneal expression of methylglyoxal-induced AGEs, 
RAGE, VEGF, as well as of nuclear factor-κB (NF-κB) and interleukin-6 (IL-6). The 
peritoneal accumulation of AGEs and RAGE in uraemia may be not so surprising, since it is 
now well recognized that the uraemic state is associated with increased generation of 
glucose-derived dicarbonyl compounds (such as glyoxal, methylglyoxal, or 3-
deoxyglucosone), which are strong inducers of AGEs (Miyata et al., 1999; Miyata et al., 2001) 
(Fig. 1). In turn, binding of AGEs to RAGE on mesothelial cells can activate NF-κB and 
increase the production of NF-κB-controlled inflammatory cytokines, including IL-6 
(Nevado et al., 2005).  
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Fig. 1. Effect of reactive carbonyls and advanced glycation end-products on VEGF release by 
mesothelial cells. 
4. Mesothelial cell phenotype and VEGF expression 
It is now clear that mesothelial cells may undergo some phenotypic changes both in vitro 
and in vivo. These changes are related to distinct biological programmes activated by cells 
exposed to environmental challenges. The exact context at which certain stimuli trigger a 
given cellular response is not fully understood. Nevertheless, increasing evidence suggest 
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that such reactions may occur also in the milieu of PD. Interestingly, transforming growth 
factor-ǃ (TGF-ǃ) has emerged as a mediator being critically involved at several steps of these 
pathways.  
4.1 Epithelial-to-mesenchymal transition 
During epithelial-to-mesenchymal transition (EMT) epithelial cells adapt a fibroblast-like 
phenotype. It includes the loss of distinctive apical-basal cell polarity, disassembly of tight 
intercellular junctions, and the acquirement of ability to migrate and shape extracellular 
matrix. Mounting evidence indicate that during PD mesothelial cells differentiate into 
submesothelial fibroblasts and impact on the underlying stroma and vasculature (Aroeira et 
al., 2007). Mesothelial cells isolated from dialysate effluent of PD patients were found to 
exhibit phenotypes ranging from the typical epithelial cobblestone-like appearance to the 
fibroblast spindle-like morphology (Yanez-Mo et al., 2003). The occurrence of fibroblast-like 
mesothelial cells increased with time on PD (Yanez-Mo et al., 2003) and was greater in 
patients who exhibited increased peritoneal permeability (Aroeira et al., 2005) or received 
PD solutions with high GDP concentrations (Aroeira et al., 2009; Bajo et al., 2011). The role 
of mesothelial cell phenotypic conversion in inducing functional alterations in peritoneal 
transport could be linked to the augmented VEGF and TGF-ǃ1 release. Mesothelial cells 
with fibroblast-like morphology were found to release significantly more TGF-ǃ1 and VEGF 
when propagated ex vivo compared to cells with classic epithelioid appearance (Aroeira et 
al., 2005; Bajo et al., 2011). A precise study with the use of immunofluorescence-aided laser 
capture microdissection confirmed that phenotypic changes in rat mesothelial cells occurred 
after adenoviral over-expression of TGF-ǃ1 in the peritoneum and were associated with 
increased VEGF expression (Zhang et al., 2008). The process was largely mediated through 
Smad3, a crucial element of the TGF-ǃ signalling pathway (Patel et al., 2010a). These data 
indicate that the gradual accumulation of transdifferentiated mesothelial cells in the 
peritoneum of PD patients may favour the development of excessive peritoneal 
vascularization and/or permeability.  
Studies on the molecular mechanisms coordinating EMT identified TGF-ǃ1 and bone 
morphogenetic protein-7 (BMP-7) as the key mediators (Zavadil & Bottinger, 2005; Zeisberg 
et al., 2003). As in other cell types, TGF-ǃ1 was shown to induce EMT in mesothelial cells 
both in vitro (Yang et al., 2003) and in vivo (Margetts et al., 2005; Patel et al., 2010a; Zhang et 
al., 2008). In contrast, BMP-7 was found to act as an inhibitor of EMT and blocked the 
mesothelial cell conversion (Loureiro et al., 2010; Vargha et al., 2006; Yu et al., 2009). 
Interestingly, it has recently been demonstrated that PD fluids with high GDP content 
induced EMT in mesothelial cells either during short-term direct in vitro exposure or 
following chronic PD regimen (Bajo et al., 2011). This finding was in line with earlier 
observations of EMT in the peritoneal membrane of rats treated with chronic intraperitoneal 
administration of methylglyoxal (Hirahara et al., 2009). The process was associated with 
increased peritoneal expression of TGF-ǃ and RAGE. Interestingly, in uraemic rats the 
inhibition of signalling from RAGE decreased the extent of mesothelial EMT and TGF-ǃ 
expression (De Vriese et al., 2006). Moreover, PD fluid-induced EMT of mesothelial cells in 
rats could be substantially reduced by peritoneal rest (Yu et al., 2009), which has long been 
advocated as a means of restoring ultrafiltration in patients with the hyperpermeable 
peritoneum (de Alvaro et al., 1993; Rodrigues et al., 2002). It has also been demonstrated that 
PD fluid-induced EMT was associated with increased signalling from Notch receptors in 
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mesothelial cells and the process was mediated through TGF-ǃ1 (Zhu et al., 2010). Notch 
receptors are involved in the determination of cell fate, differentiation, and maintenance. 
The inhibition of Notch signalling resulted in the attenuation of both TGF-ǃ1-induced EMT 
in vitro and PD fluid-induced EMT and peritoneal fibrosis in vivo (Zhu et al., 2010). 
Importantly, in both processes, the blockade of Notch led to a decrease in mesothelial cell 
VEGF expression. In a recent intriguing study (Patel et al., 2010b), platelet derived growth 
factor B (PDGF-B) was found to induce some, but not all, features of EMT in mesothelial 
cells. They included, however, increased VEGF expression.  
4.2 Cell senescence 
Gradual senescence of cells, which can easily be seen in vitro, has been believed to reflect the 
process of organismal aging. Extensive studies over the past decade have revealed, 
however, that cellular senescence is a more general phenomenon. It appears to be a cellular 
stress response set off by factors that may put the integrity of the genome in danger 
(Campisi, 2010). They include DNA breaks, dysfunctional telomeres and mitochondria, 
oxidative stress, disrupted chromatin, or excessive mitogenic stimulation. The hallmark of 
cellular senescence is an essentially irreversible growth arrest. As this prevents the 
transmission of potentially oncogenic mutations to daughter cells, the senescence response 
is thought to have evolved as a powerful cancer suppression mechanism. Other features of 
senescence include an enlarged morphology, the expression of senescence-associated ǃ-
galactosidase (SA-ǃ-gal), and the up-regulation of p16, a cyclin-dependent cell cycle 
inhibitor.  
Human peritoneal mesothelial cells in vitro enter the senescent state relatively quickly 
(Ksiazek et al., 2006). The process does not result from critical telomere shorthening (Ksiazek 
et al., 2007c), but is associated with extensive accumulation of DNA double-strand breaks in 
non-telomeric DNA regions. The damages are most likely caused by oxidative stress 
(Ksiazek et al., 2008b), which is viewed as one of the main triggers of premature senescence. 
As increased generation of reactive oxygen species occurs in hyperglycaemia (Bashan et al., 
2009), it was logical to examine how glucose impacted on senescence of mesothelial cells. It 
turned out that chronic exposure to high glucose accelerated the development of senescent 
features in mesothelial cells, and the effect could be largely prevented by antioxidants 
(Ksiazek et al., 2007a). Interestingly, a further downstream mediator of the process appeared 
to be TGF-ǃ1, since some features of the high glucose-induced senescent phenotype could be 
abolished by anti-TGF-ǃ antibodies or reproduced by exogenous TGF-ǃ1 (Ksiazek et al., 
2007b).  
The presence of senescent mesothelial cells in vivo is only scarcely documented. Cells 
expressing SA-ǃ-Gal were found in freshly explanted human omenta (Ksiazek et al., 2008b), 
in mesothelial cell imprints from mice exposed to PD fluids (Gotloib et al., 2003) or in 
mesothelial cell derived from PD effluents (Gotloib et al., 2007). The detection of senescent 
cells following in vivo exposure to PD fluids or after in vitro exposure to high glucose rises 
an interesting question of whether dialysate glucose and/or glucose derivatives promote the 
senescence of mesothelial cells. Some date indicate that direct exposure to GDP-containing 
PD fluid may, indeed, result in increased expression of SA-ǃ-Gal in mesothelial cells 
(Witowski et al., 2008).  
The potential significance of such a change in the mesothelial cell phenotype is that 
senescent cells display an altered pattern of secretion of various cytokines, growth factors, 
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proteases, and matrix components. The senescence-associated secretory phenotype may 
contribute to tissue dysfunction and pave the way for other pathologies (Coppe et al., 2010). 
VEGF has been identified as one of the mediators released at increased levels by senescent 
cells (Coppe et al., 2006). As a matter of fact, senescent mesothelial were also found to 
release significantly more VEGF than their pre-senescent counterparts (Witowski et al., 
2008). Moreover, media obtained from cultures of senescent mesothelial cells promoted 
endothelial cell growth to a greater degree compared with young cells (Ksiazek et al., 
2008a). The increase in VEGF secretion by senescent mesothelial cells could be partly related 
to the senescence-associated oxidative stress, since the antioxidant precursors of glutathione 
were found to decrease VEGF release (Witowski et al., 2008). It could also be mediated by 
the augmented activity of TGF-ǃ1 observed in senescence (Ksiazek et al., 2007b). In this 
respect TGF-ǃ1 has been shown to induce VEGF in many cell types, including mesothelial 
cells (Szeto et al., 2005).  
An interesting aspect of the process delineated above is the involvement of TGF-ǃ1 in both 
EMT and cellular senescence. Intriguingly enough, TGF-ǃ1 may also act as a mediator of 
apoptosis (Siegel & Massague, 2003). Indeed, TGF-ǃ1 was found to increase the rate of 
apoptosis in mesothelial cells, probably by down-regulating the expression of an anti-
apoptotic gene bcl-2l (Szeto et al., 2006). Therefore, it remains to be elucidated how cells read 
TGF-ǃ1 signals so that the response proceeds along a given pathway. Furthermore, it is not 
clear whether there is some relationship between the resulting processes. It has been 
suggested that the senescence-associated secretory phenotype may promote EMT in 
neighbouring cells (Coppe et al., 2008).  
5. VEGF polymorphism 
The Vegf gene is a highly polymorphic gene with several variations identified in a 5’-
promotor region of the gene (Brogan et al., 1999). Such polymorphisms are thought to bear 
functional significance and may, for example, affect VEGF production by mononuclear 
leukocytes (Watson et al., 2000) or malignant cells (Schneider et al., 2009). Several known 
Vegf polymorphisms were analysed in the context of PD. They were found to have no 
association with baseline permeability of the peritoneal membrane at the start of PD 
(Gillerot et al., 2005; Maruyama et al., 2007; Szeto et al., 2004). Interestingly, however, 
patients with the A allele at –2578 position of the Vegf gene had higher mRNA VEGF 
expression in the sediment of effluent cells compared to the individuals with the C allele 
(Szeto et al., 2004). Moreover, this genotype was associated with a gradual increase in 
peritoneal transport over time and with greater patient mortality. The data suggest that 
certain genotypes may predispose to increased local VEGF release in response to PD 
environment and thus impact on peritoneal membrane function. Since mesothelial cell EMT 
or senescence are associated with increased secretion of VEGF, it would be interesting to 
know whether certain genotypes have an effect on the incidence of such changes in PD 
patients.  
6. Conclusions 
The mesothelium is the main source of peritoneal VEGF. By secreting VEGF, mesothelial 
cells impact on peritoneal vasculature. In PD patients the exposure of mesothelial cells to 
uraemic environment, bioincompatible dialysis fluids, and the bouts of infection may 
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change the secretory phenotype of mesothelial cells so that they release more VEGF. In some 
patients (possibly with a certain genetic background), VEGF secretion may become 
excessive, and mediate pathological angiogenesis. On the other hand, however, VEGF-
induced neoangiogenesis cannot be viewed as the sole culprit of the peritoneal membrane 
dysfunction. Computer simulations suggest that an increase in peritoneal exchange surface 
area alone will not account for a massive decrease in drained volumes (Rippe et al., 1991). 
One has to bear in mind, however, there exists a tight link between angiogenesis and fibrosis 
(Wynn, 2007). In fact, detailed studies of peritoneal biopsies showed that the degree of 
peritoneal fibrosis correlated with greater vascular density and, conversely, fibrosis 
occurred infrequently in the absence of vasculopathy (Williams et al., 2002). Thus, the 
contribution of mesothelial cell-derived VEGF to the peritoneal membrane dysfunction is 
probably multifactorial, and is related both to a direct increase in peritoneal permeability 
and the involvement in peritoneal fibrosis (Fig. 2).  
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Fig. 2. Possible impact of PD environment on mesothelial cell VEGF expression and 
peritoneal membrane dysfunction. 
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